Viking Therapeutics Inc (VKTX) Expected to Announce Earnings of -$0.10 Per Share

Brokerages expect Viking Therapeutics Inc (NASDAQ:VKTX) to announce earnings of ($0.10) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Viking Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.12) and the highest estimate coming in at ($0.09). Viking Therapeutics reported earnings of ($0.14) per share in the same quarter last year, which indicates a positive year over year growth rate of 28.6%. The business is scheduled to issue its next earnings results on Wednesday, March 6th.

According to Zacks, analysts expect that Viking Therapeutics will report full-year earnings of ($0.43) per share for the current financial year, with EPS estimates ranging from ($0.45) to ($0.40). For the next year, analysts forecast that the company will post earnings of ($0.46) per share, with EPS estimates ranging from ($0.55) to ($0.34). Zacks’ EPS averages are an average based on a survey of analysts that cover Viking Therapeutics.

A number of research firms recently commented on VKTX. William Blair reiterated a “buy” rating on shares of Viking Therapeutics in a report on Tuesday, November 13th. Roth Capital set a $23.00 price target on shares of Viking Therapeutics and gave the company a “buy” rating in a report on Friday, November 9th. Maxim Group reiterated a “buy” rating and issued a $28.00 price objective on shares of Viking Therapeutics in a research note on Thursday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $31.00 price objective on shares of Viking Therapeutics in a research note on Thursday, November 8th. Finally, B. Riley assumed coverage on shares of Viking Therapeutics in a research report on Tuesday, December 11th. They issued a “buy” rating and a $16.00 target price for the company. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $26.29.

A number of institutional investors have recently added to or reduced their stakes in the stock. Knott David M boosted its stake in Viking Therapeutics by 0.6% during the 4th quarter. Knott David M now owns 238,102 shares of the biotechnology company’s stock worth $1,821,000 after acquiring an additional 1,502 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Viking Therapeutics by 0.4% during the fourth quarter. Bank of New York Mellon Corp now owns 387,039 shares of the biotechnology company’s stock worth $2,960,000 after buying an additional 1,555 shares during the last quarter. TIAA CREF Investment Management LLC increased its holdings in Viking Therapeutics by 1.6% during the third quarter. TIAA CREF Investment Management LLC now owns 98,296 shares of the biotechnology company’s stock worth $1,712,000 after buying an additional 1,562 shares during the last quarter. Court Place Advisors LLC increased its holdings in Viking Therapeutics by 18.5% during the fourth quarter. Court Place Advisors LLC now owns 12,800 shares of the biotechnology company’s stock worth $98,000 after buying an additional 2,000 shares during the last quarter. Finally, Meeder Asset Management Inc. boosted its position in Viking Therapeutics by 63.5% during the fourth quarter. Meeder Asset Management Inc. now owns 7,309 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 2,839 shares during the period. 60.23% of the stock is currently owned by institutional investors and hedge funds.

Viking Therapeutics stock traded up $0.01 during midday trading on Friday, reaching $9.07. 3,314,929 shares of the stock traded hands, compared to its average volume of 2,814,698. The firm has a market capitalization of $647.43 million, a price-to-earnings ratio of -11.48 and a beta of 2.76. Viking Therapeutics has a fifty-two week low of $3.69 and a fifty-two week high of $24.00.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

See Also: Bollinger Bands

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.